Fatty acid binding protein facilitates sarcolemmal fatty acid transport but not mitochondrial oxidation in rat and human skeletal muscle
- 25 June 2007
- journal article
- Published by Wiley in The Journal of Physiology
- Vol. 582 (1), 393-405
- https://doi.org/10.1113/jphysiol.2007.135301
Abstract
The transport of long-chain fatty acids (LCFAs) across mitochondrial membranes is regulated by carnitine palmitoyltransferase I (CPTI) activity. However, it appears that additional fatty acid transport proteins, such as fatty acid translocase (FAT)/CD36, influence not only LCFA transport across the plasma membrane, but also LCFA transport into mitochondria. Plasma membrane-associated fatty acid binding protein (FABPpm) is also known to be involved in sacrolemmal LCFA transport, and it is also present on the mitochondria. At this location, it has been identified as mitochondrial aspartate amino transferase (mAspAT), despite being structurally identical to FABPpm. Whether this protein is also involved in mitochondrial LCFA transport and oxidation remains unknown. Therefore, we have examined the ability of FABPpm/mAspAT to alter mitochondrial fatty acid oxidation. Muscle contraction increased (P < 0.05) the mitochondrial FAT/CD36 content in rat (+22%) and human skeletal muscle (+33%). By contrast, muscle contraction did not alter the content of mitochondrial FABPpm/mAspAT protein in either rat or human muscles. Electrotransfecting rat soleus muscles, in vivo, with FABPpm cDNA increased FABPpm protein in whole muscle (+150%; P < 0.05), at the plasma membrane (+117%; P < 0.05) and in mitochondria (+80%; P < 0.05). In these FABPpm-transfected muscles, palmitate transport into giant vesicles was increased by +73% (P < 0.05), and fatty acid oxidation in intact muscle was increased by +18% (P < 0.05). By contrast, despite the marked increase in mitochondrial FABPpm/mAspAT protein content (+80%), the rate of mitochondrial palmitate oxidation was not altered (P > 0.05). However, electrotransfection increased mAspAT activity by +70% (P < 0.05), and the mitochondrial FABPpm/mAspAT protein content was significantly correlated with mAspAT activity (r = 0.75). It is concluded that FABPpm has two distinct functions depending on its subcellular location: (a) it contributes to increasing sarcolemmal LCFA transport while not contributing directly to LCFA transport into mitochondria; and (b) its primary role at the mitochondria level is to transport reducing equivalents into the matrix.Keywords
This publication has 53 references indexed in Scilit:
- The potential for mitochondrial fat oxidation in human skeletal muscle influences whole body fat oxidation during low-intensity exerciseAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- Coimmunoprecipitation of FAT/CD36 and CPT I in skeletal muscle increases proportionally with fat oxidation after endurance exercise trainingAmerican Journal of Physiology-Endocrinology and Metabolism, 2006
- Mitochondrial efficiency in rat skeletal muscle: influence of respiration rate, substrate and muscle typeActa Physiologica Scandinavica, 2005
- Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscleBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2005
- The subcellular compartmentation of fatty acid transporters is regulated differently by insulin and by AICARFEBS Letters, 2005
- A Novel Function for Fatty Acid Translocase (FAT)/CD36Journal of Biological Chemistry, 2004
- Different mechanisms can alter fatty acid transport when muscle contractile activity is chronically alteredAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Triacylglycerol accumulation in human obesity and type 2 diabetes is associated with increased rates of skeletal muscle fatty acid transport and increased sarcolemmal FAT/CD36The FASEB Journal, 2004
- Increased Rates of Fatty Acid Uptake and Plasmalemmal Fatty Acid Transporters in Obese Zucker RatsJournal of Biological Chemistry, 2001
- CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolismJournal of Clinical Investigation, 2001